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Abstract 
Vietnam has been a highly endemic country with viral hepatitis B virus (HBV) infection. 
An estimated 8.4 million people lived with chronic HBV infection leading to approximately 
23,300 HBV-related deaths in Vietnam in 2005 (Van T T Nguyen, 2012). Estimation of 
projected number of HBV-related liver cirrhosis and hepatocellular carcinoma in 2025 was 
58,650 and 25,000, respectively, resulting in 40,000 deaths (Van Thi Thuy Nguyen, Law, & 
Dore, 2008).  
Vaccination under the Expanded Program on Immunization (EPI) is the primary means of 
preventing both vertical and horizontal HBV infection in children in Vietnam. The Ministry of 
Health (MOH) recommends that all infants receive a birth dose of Hepatitis B monovalent 
vaccine (HepB-BD) within 24 hours of birth, followed by 3 doses of pentavalent DPT-HepB-Hib 
combination vaccine at 2, 3, and 4 months of age. An estimation of up to 51,000 deaths could be 
prevented and 265,000 chronic infections could be avoided in Vietnam every year if timely birth 
dose and the 3 following doses of HepB vaccines was given to 95% of the birth cohort in that 
year (Li et al., 2016). 
Having been implemented for 16 years since 2003, HepB-BD immunization practice in 
Vietnam still shows low profile (<80% countrywide and 20-40% in mountainous areas) and 
encounters multiple challenges for it to be fully adopted and implemented to facilitate the 
achievement of nationwide public health impact on reducing burden of HepB disease. Influential 
factors to HepB-BD coverage rates in the country have been found to include health system, 
healthcare provider, recipient of care, and social related factors. Systematic identification and 
accurate characterization of the facilitators and barriers to full implementation of HepB-BD 
immunization policy in various healthcare settings and local contexts could inform effective 
multi-level multifaceted implementation strategies for increasing timely HepB-BD coverage 
rates. Consolidated Framework for Implementation Research (CFIR) can be a useful tool to 
guide the development of such implementation strategies. 
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INTRODUCTION AND BACKGROUND 
Hepatitis B and Hepatitis B Virus 
Hepatitis B (HepB) is the most common serious liver infection in the world which is 
caused by hepatitis B virus (HBV). According to World Health Organization (WHO), an 
estimated 257 million people (about 3.5% the world general population) were living with chronic 
HBV infection in 2015, resulted in almost 900,000 deaths, mostly from complications including 
cirrhosis and hepatocellular carcinoma (World Health Organization, 2018). 
HBV is a small DNA virus that belongs to the Hepadnaviriade family. The virus contains 
an outer envelope and inner core. The outer envelope of the virus is comprised of a surface 
protein called the HepB surface antigen (HBsAg); this is a serologic marker of chronic HBV 
infection. The HBsAg can be detected by a simple blood test and a positive result indicates a 
person is infected with the HBV. The inner core of the virus is a protein shell referred to as the 
HepB core antigen (HBcAg), which contains the HBV DNA and enzyme used in viral 
replication (Hepatitis B Foundation, n.d.). In infectious individuals, HBV can also produce HepB 
e antigen (HBeAg), which is a marker of infectivity (Figure 1). HBV is relatively heat stable, 
highly infectious and can remain infectious for at least one week in the environment (World 
Health Organization, 2017b).  
The HBV can cause an acute or chronic infection. Acute infection may last several 
weeks, or up to 6 months in some cases. Most healthy adults and children older than 5 years are 
able to produce antibodies against HBsAg and HbcAg (serologically detected as anti-HBs and 
anti-HBc) and fight off HBV infection without treatment. Chronic infection lasts for a long time, 
which occurs when the infected body is not able to fight off HBV and the virus does not go 
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away. Chronically infected individuals have a 15%-25% estimated lifetime risk of developing 
cancer or cirrhosis, depending upon age at infection (World Health Organization, 2009). 
HBV can be transmitted by exposure of mucosal membranes or non-intact skin to 
infected blood or other specific body fluids (saliva, semen and vaginal fluid). Transmission can 
occur prenatally from mother to child or from person to person (World Health Organization, 
2017b). While HBV infection in adulthood leads to chronic hepatitis in <5% of cases, the 
development of chronic infection is very common in infants infected from their mothers and in 
children infected before 6 years of age. According to the WHO, 80-90% of infants infected 
during the first year of life develop chronic infections, and 30-50% of children infected before 
the age of 6 years develop chronic infections (World Health Organization, 2018). The risk of 
HBV perinatal transmission increases when mono-infected mothers express HBeAg or have a 
high HBV DNA viral load (≥104 IU/ml) (Breakwell, Tevi-Benissan, Childs, Mihigo, & Tohme, 
2017), or mothers are co-infected with HIV (Spearman et al., 2017). The risk of transmitting 
HBV to child from HBsAg-positive HBeAg-positive mothers may increase by 2 fold when 
compared to that from HBsAg-positive HBeAg-negative mothers; equally, the risk of 
transmission from HIV/HBV co-infected mother to child may increase by 2 fold when compared 
to that from HBV mono-infected mothers (Sangaré et al., 2009). In Asia, 70% to 100% infants 
born to mothers who are positive for both HBsAg and HBeAg are at risk of acquiring infection, 
compared to only 5 to 30% transmission risk in those born to HBsAg-positive HBeAg-negative 
mothers (World Health Organization, 2017b). About 90% of babies born to HBsAg-positive 
HBeAg-positive mothers become chronically infected, compared with about 35% of babies born 
to HBsAg positive HBeAg negative chronically infected mothers (World Health Organization, 
2009).  
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This paper will address vaccination as a main approach in the prevention of childhood 
HBV infection in Vietnam, especially prevention of mother to child transmission (PMTCT). 
Background information about the prevalence of HepB disease in Vietnam and in-country 
policies on HepB screening, treatment and vaccination will be presented to give a better 
understand of HepB epidemiology and control measures in the prevention of HepB infection in 
in the country.  
 
Prevalence of Hepatitis B disease in Vietnam 
According to the WHO, Vietnam has been a highly endemic country with viral hepatitis 
infection. In 2013, viral hepatitis (including both B and C) was the 3
rd
 cause of deaths in 
Vietnam, while the disease ranked number 7 among the top 10 causes of global mortality (World 
Health Organization Regional Office for the Western Pacific, 2018). An estimated 8.4 million 
people lived with chronic HBV infection leading to approximately 23,300 HBV-related deaths in 
Vietnam in 2005 (Van T T Nguyen, 2012). Estimation of projected number of HBV-related liver 
cirrhosis and hepatocellular carcinoma in 2025 was 58,650 and 25,000, respectively, resulting in 
40,000 deaths (Van Thi Thuy Nguyen, Law, & Dore, 2008).  
The cost attributed to HepB related diseases in the country in 2008 was approximately 
4.4 billion US dollars, with 70% of this amount spent on the treatment of the disease including 
costs for clinic visits, laboratory tests and procedures, drug costs, and other costs during hospital 
stays (Tu, Woerdenbag, et al., 2012). Due to heavy disease burden, HepB has been closely 
monitored under national surveillance program. Number of HepB new cases and deaths, 
accumulative number of infected cases, and accumulative number of deaths from each province 
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have to be reported to the MOH on monthly and yearly basis (Vietnam Ministry of Health, 
2010). 
Prevalence of HBsAg in Vietnam ranges from 10% to 20% in general adult population 18 
– 87 years of age, 20% to 40% among injecting drug users and HIV positive patients (Van T T 
Nguyen, 2012), and 8% to 10% in pregnant women aged 15 to 49 years (Goto et al., 2005; Lan et 
al., 2008). In pre-vaccination era, the prevalence of HBV infection in healthy children of 0 to 15 
age group ranged from 12.5% to 19.5% depending on areas, with the highest prevalence in 
children in rural areas (Hipgrave et al., 2003; Van T T Nguyen, 2012). According to a survey 
conducted in rural communes in Thanh Hoa province in 1998 (before the national immunization 
program was implemented), more than 35% children from 0 to 6 years old had current or 
previous infection with HBV, and rates of HBeAg among those carried HBsAg were 85.1% in 
infants (9 to ≤18 months old) and 88.1% in children (4 to ≤6 years old) (Hipgrave et al., 2003). 
Data from random sampling surveys across the country estimated HBsAg prevalence among 
children born during 2000-2003 (in the introduction phase of HepB vaccine with low birth dose 
coverage) who was unvaccinated was 3.64% with no significant difference between males and 
females (T. H. Nguyen et al., 2014). HBsAg prevalence in 5-year-old children by birth cohort in 
the country in post-vaccination era was about 3.6% in 2006, 2.2% in 2010, and 1.6% in 2012 
(World Health Organization Regional Office for the Western Pacific, 2018).  
Major routes of HBV transmission in Vietnam are either horizontal from an infected 
child or family member to an uninfected child during the first 5 years of life, or vertical from 
mother to child at birth (perinatal transmission) (Van T T Nguyen, 2012; World Health 
Organization, 2018). In the north mountainous areas of the country, nearly 1 out of 3 households 
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had at least one person currently have HepB; that would increase the risk of getting childhood 
HBV infection in this region (Van T T Nguyen, 2012).  
 
Policies on control of childhood HepB infection in Vietnam 
Vaccination is the primary means of preventing HBV infection in children in Vietnam. 
Infant HepB vaccination has been included in the Expanded Program on Immunization (EPI) 
since 1997 with limited coverage in 2 provinces and 35 districts due to vaccine shortage. In 
2003, with the help of Global Alliance for Vaccines and Immunization (GAVI), HepB 
vaccination coverage has increased to all the 61/61 cities and provinces and 646/646 districts, 
and in 2010 to all the 63/63 cities and provinces and 690/690 districts. Infant HepB vaccination 
within 24 hours of birth (birth dose – BD) started being offered under the EPI in 2003 then has 
implemented nationwide since 2006. Vietnam MOH recommends that all infants receive HepB-
BD within 24 hours of birth regardless settings and geographic areas (Vietnam Ministry of 
Health, 2012).  
From 2003 to 2009, the strategy for preventing vertical and horizontal transmission of 
HBV in children is administrating timely HepB-BD within the first 24 hours after birth plus 2 
additional doses within 2-month intervals with monovalent HepB vaccine under the EPI 
(vaccination time: birth, 2, 4 months) (T. D. Nguyen et al., 2015). A monovalent HepB vaccine 
produced locally was used for HepB immunization under the EPI for either birth dose or 
following doses. Since 2010, Vietnam EPI started to offer HepB vaccination for infants from 2 
months of age in the form of a single-dose of the combination pentavalent vaccine against 
Diphtheria - Pertussis - Tetanus (DTP), HepB and Haemophilus influenzae B (DTP- Hep B-Hib) 
which has been imported from outside and cannot be administered at birth (Table 1). The 
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monovalent HepB vaccine that was previously used as part of the EPI has still been available for 
administration at birth to newborns in addition to the pentavalent vaccine.  
There are two prevention approaches that can apply to HBV PMTCT: first, test and treat 
HBV positive mothers to reduce viral load to non-detectable level, thus HBV cannot be 
transmitted to their baby during delivery; and second, vaccinate the infants as soon as possible, 
preferably during 24 hours after birth. The WHO recommends that in settings with ≥5% HBsAg 
seroprevalence in the general population, HBsAg serological testing is routinely offered to all 
pregnant women in antenatal clinics, with linkage to prevention, care and treatment services 
(World Health Organization, 2017a). Although evidence shows that antiviral treatment in the 
third trimester of pregnancy can lower viral load in women and decrease perinatal HBV 
transmission from mothers with very high viral load, currently the WHO does not recommend 
the routine use of antiviral treatment in the third trimester of pregnancy for PMTCT (World 
Health Organization, 2017b).  
In Vietnam, currently there is no national HepB testing guideline for general population 
or pregnant women, nor guideline on HBV control for women of childbearing age, especially for 
pregnant women (Vietnam Ministry of Health, 2015). However, HBV rapid diagnostic tests 
(RDTs) are widely available in the country in the public and private sectors and at all levels of 
the health systems, except at the level of commune health station. Vietnam MOH recommends 
that all pregnant women get screened for HBsAg; those tested positive with HBsAg then further 
get tested for HBeAg and HBV DNA in week 28 and get treated with tenofovir disoproxil 
fumarate (TDF) till delivery, and the newborn is given timely HepB-BD and following 3 
additional doses (Vietnam Ministry of Health, 2014, 2015).     
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Recently, in 2018, Vietnam MOH issued a Decision on the approval of the National 
Action Plan on the elimination of HIV, Hepatitis B and syphilis transmitted vertically from 
mother to child (Vietnam Ministry of Health, 2018). As stated in this action plan, prevalence of 
HBsAg positive children less than 5 years of age is targeted at ≤0.1% by 2030, and the 
percentage of infants getting within 24-hour HepB-BD at least 90% by 2030, which meets the 
WHO target (World Health Organization, 2017b). 
 
The importance of timely HepB-BD immunization in PMTCT 
  Infants of HBV positive mothers are the most vulnerable population who likely get 
infected with HBV and to develop HepB chronic disease such as cirrhosis and/or liver cancer. 
While more than 80% of infants who get infected with HBV in the first year of life will develop 
chronic disease, only less than 5% of population who are infected as adults will develop chronic 
infection. This observation emphasizes the importance of public health attention and prevention 
for infants less than 1 year of age from HBV infection, especially those who has mother positive 
with HBV infection.  
HBV transmission from mother to child (TMTC) can be effectively prevented by the 
timely administration of HepB vaccine; vaccines against HepB have been available since 1982 
which is 95% effective in preventing infection and the development of chronic disease and liver 
cancer due to HepB (World Health Organization, 2009). The WHO recommends that all infants 
receive 1 monovalent HepB-BD followed by either 2 or 3 doses of monovalent or HepB-
containing combination vaccine doses administered during the same visits as the first and third 
doses of DTP-containing vaccines, or during the same visits as the 3 doses of DTP-containing 
vaccines (World Health Organization, 2017b). Full administration of timely HepB-BD followed 
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by 3 additional doses can prevent 85-90% of MTCT cases. Even if HepB vaccination was 
administered on day 7 following birth, the risk of HBV infection for infants born to HBsAg-
positive mothers was still higher than when the first dose of HepB vaccine was given on day 1-3 
following birth (World Health Organization, 2009). In countries where the proportion of 
Hepatitis B positive mothers is high, if the first dose is not given within the first 24 hours of life, 
the protection rate of Hepatitis B vaccine could be reduced as low as only 50% to 75% (Nelson, 
Easterbrook, & McMahon, 2016). A study in Vietnam in children less than 15 years of age have 
shown that HBsAg prevalence in those vaccinated with 3 doses without birth dose was 
significantly higher than those with 3 doses with birth dose, and those receiving HepB vaccine 
>7 days after birth had twice higher HBsAg prevalence than those vaccinated 0-1 day after birth 
(T. H. Nguyen et al., 2014). In another study in Africa, about 10% of children born to HIV/HBV 
co-infected mothers became HBV-infected (HBV DNA positive) by 48 weeks of age, despite 
vaccination administered at 6 weeks (Chasela et al., 2014).  
It is recognized that evidence-based practices (EBPs) take on average 17 years to be 
incorporated into routine health care practice, and there are gaps between research and 
implementation (Morris, Wooding, & Grant, 2011). Having implemented for 16 years since 
2003, HepB-BD immunization practice in Vietnam still encounters multiple challenges for it to 
be fully adopted and implemented to facilitate the achievement of nationwide public health 
impact on reducing burden of HepB disease.   
Addressing timely HepB-BD vaccination (within 24 hours of birth) as a strategy for HBV 
PMTCT, this paper will review the situation of HepB-BD immunization in Vietnam and 
associated influential factors to the implementation of timely HepB-BD practice. Results from a 
systematic review of literature published in English and Vietnamese on the rates of HepB-BD 
 Page 9 of 54 
 
coverage in the country from 2003 (when HepB-BD was introduced to the national 
immunization program in Vietnam) up to date and potential factors that might influence these 
rates will be presented. This paper will also suggest using an implementation research framework 
as a tool to guide the identification of systematic facilitators and barriers to the HepB-BD 
immunization routine practice in Vietnam.   
 
SITUATION OF HEPATITIS B BIRTH DOSE IMMUNIZATION IN 
VIETNAM AND INFLUENTIAL FACTORS TO IMPLEMENTATION  
Literature review and selection criteria 
A systematic review was conducted with English language publications from online 
electronic databases that included Pubmed, Global Health, Cochrane, Embase, and Scopus. 
Keyword for searching literature were “Hepatitis B” AND “birth dose” OR “vaccin*” OR 
“immune*” OR “birth” AND “Vietnam*” OR “Viet Nam” OR “Viet*”. Publications from the 
WHO and other international health organizations about HepB-BD in Vietnam have been 
searched online and manually. Title, abstract, full text, and cited references of articles found 
were reviewed for final eligibility. 
For literature in Vietnamese language, both electronic and manual search was conducted 
on websites of Vietnam MOH and Department of Health (DOH), Journal of Preventive 
Medicine, and in library of National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, 
Vietnam. Publications in Vietnamese could include journal articles and reports from Vietnam 
MOH and DOH, other institutions and organizations, and master and doctoral dissertations. Title, 
abstract, full text, and cited references of articles found were reviewed for final eligibility.  
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Since implementation research on HepB-BD in Vietnam is limited, any study addressing 
HepB-BD vaccination practice in Vietnam and any public health intervention conducted in 
Vietnam related to the implementation of HepB-BD immunization to Vietnamese infants was 
selected regardless of settings, sample size and study designs (except clinical trials that were 
restricted to the evaluation of the efficacy of the vaccine to infants without analysis of influential 
factors on vaccine coverage). The literature review sought to address 4 main questions:  What is 
the effectiveness of national vaccination policy and program on HepB-BD coverage?; What is 
the cost associated with HepB-BD implementation?; What are influential factors on the rate of 
HepB-BD coverage?; and What interventions or strategies have been used to increase the rate 
HepB-BD coverage in the country? (Table 2).   
One WHO global monitoring report in English has been found to summarize the rates of 
HepB-BD in Vietnam from 2007 to 2017 (Figure 2). One pending-to-publication WHO report on 
viral hepatitis situation and response in Vietnam (World Health Organization Regional Office for 
the Western Pacific, 2018) - which was recently presented in the National Hepatitis Technical 
Working Group Planning Meeting to develop an Action Plan on Prevention of Viral Hepatitis in 
Vietnam period 2020-2025 held on April 5, 2019 in Hanoi, Vietnam - summarized the situation 
following HepB-BD implementation in the country and discussed several challenges associated 
with the routine practice. Seven publications in English have been found from online electronic 
databases, of which 5 were eligible for further review (Table 3). Among them, 2 publications 
examined the effectiveness of vaccination policy and program on HepB-BD coverage at national 
level (Li et al., 2016; T. H. Nguyen et al., 2014), and 1 publication estimated the cost associated 
with HepB-BD vaccination at district and commune levels (Murakami, Van Cuong, Huynh, & 
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Hipgrave, 2008). Four publications have reported or discussed influential factors on the rates of 
HepB-BD coverage (Table 3).   
HepB-BD coverage rates in 63 cities and provinces from 2012 to 2015 have been found 
on website of the EPI (Figure 3). Due to limited capacity in literature search, only 3 publications 
in Vietnamese have been found with full text, of those 2 publications examined HepB-BD 
coverage and associated influential factors at district level (A. D. Duong, Pham, & Hoang, 2017; 
T. H. Duong, Tran, & Doan, 2016). One publication presented implementation interventions to 
the increase in HepB-BD coverage rate at provincial and district levels and reported intervention 
outcome (H. T. Duong, Nguyen, Le, & Ly, 2011).  
 
Rates of HepB-BD coverage  
In 2010, HepB3 coverage rate under the EPI was 87.5%. From 2011 to 2016, the average 
rates of HepB3 coverage in the country reached ≥ 95%, except in 2013 the percentage of 
coverage dropped to lower than 60%. However, the average rates of HepB-BD coverage have 
fluctuated over years from 2007 to 2017 with the highest rates achieved in 2012 (76%) and 2017 
(77%) and the lowest rate achieved in 2010 (21%) (Figure 2). As seen in Figure 3, among 63 
cities and provinces, HepB-BD coverage rates were lowest in provinces in the northern 
mountainous region (Lai Chau, Lang Son, Ha Giang, Cao Bang, Yen Bai, Lao Cai, Son La and 
Dien Bien), ranging from 11.3% in Cao Bang to 39.4% in Lao Cai in the first 3 quarters of 2015. 
Coverage rates in other provinces range from 30% to 73% in the last quarter of 2015.     
Results from 2009 EPI cluster surveys with children from 12 to 23 months (birth cohort 
2007) from 6 provinces across the 6 areas of the country (northern mountain, Red river delta, 
central, central highland, south east and south west) have shown low coverage for timely HepB-
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BD in 2007 birth cohort at all surveyed provinces. Total rate for the 6 surveyed provinces is 
12.3%, ranging from 1% in Lao Cai (a province in the northern mountainous area) to 28% in 
Khanh Hoa, a province in the central part of the country (T. D. Nguyen et al., 2015).  
A study by Pham and colleagues (Pham et al., 2018) showed timely HepB-BD coverage 
(within 24 hours of birth) was 46.5% in some provinces in the Mekong River Delta. A majority 
of those vaccinated were children from Kinh group which is a major ethnic group in Vietnam 
(92.2%). Another 16.5% of infants received a delayed HepB-BD 2 to 7 days after birth. 
 
Effectiveness of HepB-BD immunization in preventing childhood HBV 
infection 
HepB-BD immunization policy and implementation programs in Vietnam have been 
demonstrated as effective in reducing HBsAg prevalence in children. According to studies by 
Nguyen and colleagues on 3 birth cohorts 2000-2003, 2004-2006 and 2007-2008 (T. H. Nguyen 
et al., 2014), HBsAg prevalence among children who were unvaccinated was almost 2 times 
higher than those with 3+ doses of Hep B vaccine including a birth dose. Prevalence among 
children who received 3+ doses but lacked a birth dose was almost 0.7 times higher than those 
with 3+ doses of Hep B vaccine including a birth dose. Infants receiving HepB vaccine >7 days 
after birth had significantly higher HBsAg prevalence than those vaccinated 0-1 day after birth. 
Prevalence of HBsAg in children born from 2000 through 2008 of ethnicity groups was much 
higher than those of Kinh, a major Vietnamese ethnic group; that observation implicated that 
children in rural mountainous areas had more limited access to vaccination compared to those in 
urban areas (5.35% versus 2.1%) (T. H. Nguyen et al., 2014).  
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In 2013, due to AEFIs with pentavalent vaccine, there was a sharp decline in the rate of 
HepB vaccination including both HepB3 and HepB-BD. An estimation of >90,000 excessive 
HBV chronic infections and >17,000 deaths would occur in children born in 2013 due to the 
drop in HepB immunization coverage in 2013 compared to 2012  (Li et al., 2016). 
 
Incremental cost associated with HepB-BD implementation  
Because the vaccine is freely provided to infants by the EPI, estimated cost for HepB-BD 
immunization at vaccination sites mainly included fuel collect vaccine and to do outreach to 
clinics or homes, the cost of electricity to run domestic refrigerators for storing vaccines, official 
monthly wages, time and allowance for collecting vaccine and immunizing infants. The total 
incremental cost of HepB-BD immunization was estimated less than 0.70 USD per birth in some 
provinces in 2014, ranging from 0.01 USD to 0.68 USD from commune to commune (Murakami 
et al., 2008). 
 
Influential factors on HepB-BD immunization practice 
Multi-level factors have been discussed to directly affect HepB-BD coverage and 
timeliness. Type of birth facilities, vaccination process and practice (especially HepB-BD post-
administration recording and reporting procedure and practice) in public and private birth 
facilities including availability of vaccination services on weekends and holidays, the readily 
availability of vaccine in the facilities for timely immunization of newborns, and the 
disconnection of many private health facilities with the EPI system have been described as health 
system related influential factors (T. H. Duong, Tran, & Doan, 2016; Murakami, Van Cuong, 
Huynh, & Hipgrave, 2008; Pham et al., 2018; World Health Organization Regional Office for the 
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Western Pacific, 2018). Although delayed vaccination due to stockpiling was not reported in the 
EPI 2009 cluster survey by Nguyen and colleagues, it was clearly observed in 2003 cluster 
survey by the same group administering an EPI vaccine in remote provinces in the northern 
mountain and central highland (T. D. Nguyen et al., 2015). A lack of capacity in the health 
system to track pregnant women in communities was also found to influence timely HepB-BD 
immunization for newborns (Murakami et al., 2008). Knowledge, attitude and behavior of 
healthcare workers including confusion about contraindications for infant vaccination and 
concern about AEFIs also directly affected the HepB-BD coverage rate (A. D. Duong, Pham, & 
Hoang, 2017; T. H. Duong et al., 2016; Pham et al., 2018; World Health Organization Regional 
Office for the Western Pacific, 2018).  
Distance from home to vaccination place, transportation means, education of parents, 
family perceptions, duration that mothers stay in the facilities after giving birth (more or less 
than 24 hours), and health conditions of the newborns appeared to be main recipients of care- 
related influential factors (Pham et al., 2018, T. H. Duong et al., 2016; Murakami et al., 2008, A. 
D. Duong et al., 2017). The public knowledge and perception on AEFIs have been discussed as 
the main social influential factors to HepB-BD coverage rates (T. H. Duong et al., 2016; Li et al., 
2016; World Health Organization Regional Office for the Western Pacific, 2018). 
 
Intervention strategies used to increase the rate of HepB-BD coverage  
Only one study found to report the implementation of a multifaceted intervention strategy 
that simultaneously addressed health system, and individuals and communities, in order to 
increase the HepB-BD coverage rate (H. T. Duong et al., 2011). Health system-oriented 
interventions included training to health managers and health care workers for increasing 
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knowledge and practice on HepB-BD immunization, and providing refrigerators for storing 
HepB vaccine in facilities. Consultation to pregnant women about the benefits of HepB-BD 
vaccination was described as individual-oriented intervention. Community-oriented interventions 
included education to the public by social marketing for an increase in knowledge on HepB-BD 
and vaccination safety, and advocating for increased community engagement in adopting HepB-
BD immunization practice. This multifaceted implementation intervention strategy resulted in 
76% increase in the rate of HepB-BD coverage, from 16% before the intervention to >92% after 
1 year of implementation intervention (H. T. Duong et al., 2011). 
  
DISCUSSION 
Potential facilitators and barriers to timely HepB-BD immunization in 
Vietnam and neighboring countries 
According to the WHO, the third dose coverage of HepB vaccine (HepB3) in infancy 
reached 84% in 2015 worldwide, almost reaching the WHO target for 2030 (90%). However, 
only 39% infants received the timely HepB-BD within the first 24 hours, much lower than the 
WHO target for 2030 (90%) (Hutin, Bulterys, & Hirnschall, 2018). Some observations in 
Vietnam have shown that timely HepB-BD had the lowest proportion among children under five 
years of age compared to other vaccine (An et al., 2016; A. D. Duong et al., 2017). Although 
there have been multiple studies in Vietnam on the implementation of the national immunization 
program in general or HepB3 vaccination under the EPI, very few studies have addressed 
barriers/facilitators to the rate of HepB-BD coverage as well as specifying and testing optimal 
strategies for maximize the use of HepB vaccine for timely birth dose immunization in the 
country. 
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Studies have shown that the rates of HepB-BD vaccination are high when mothers give 
birth at a medical facility or with the help of a skilled birth attendance (Allison, Patel, & Tohme, 
2017; S. Wang, Smith, Peng, Xu, & Wang, 2016). Among the 6 WHO regions, the West Pacific, 
where Vietnam is located, showed the highest rates of institutional delivery (>90%), skilled birth 
attendance (> 90%) and HepB-BD coverage (> 80%) in 2014 (Allison et al., 2017). In 
Cambodia, promoting institutional deliveries through provision of financial incentives and 
encouraging mothers to deliver in health facilities led to an increase in timely HepB-BD 
coverage (Allison et al., 2017). A study by Duong and colleagues in Vietnam showed that 
training to skilled birth attendance to increase knowledge and practice on HepB-BD 
immunization, improving cold chain infrastructure for storing HepB vaccine in facilities, and 
organizing vaccination services twice a day or several times a day according to the number of 
shifts at birth facilities, and providing vaccination services in the weekends were among 
facilitators to an increase of HepB-BD coverage rate (H. T. Duong et al., 2011). In China, the 
policy “who delivers the infant, who has to vaccinate the infant” has been reported a facilitators 
for increasing birth dose coverage. Eight years after the implementation, the rate of infants who 
received HepB vaccine within the first 24 hours of birth in China reached 80%, and HBsAg 
prevalence in the country was less than 1% among children under 5 years of age (Liang et al., 
2013; S. Wang et al., 2016).     
In Vietnam, the rate of deliveries attended by trained health personnel in 2015 was more 
than 98% countrywide and 92% in rural and mountainous areas (Vietnam Ministry of Health, 
2017). However, the average rate of within-24-hour HepB-BD coverage across the country never 
reached 70% since implementation (Figure 2), suggesting alternative influential factors to HepB-
BD rates. Studies showed that children of Kinh ethnicity were more likely to receive timely 
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immunization completion compared with children from minority ethnic group. This observation 
indicated that different ethnicities, residential areas and socioeconomic status contributed to the 
difference in attitudes and health seeking behaviors of individuals, families or communities (An 
et al., 2016).  
Several studies conducted in rural communes in Vietnam have shown that timely 
administration of different vaccines under the EPI in general is an issue, implying that difficult 
access to villages in mountainous and remote areas are obstacles to organizing and providing 
vaccination services from place to place (A. D. Duong et al., 2017; T. H. Duong et al., 2016; T. 
D. Nguyen et al., 2015). Observation by Hipgrave and colleagues suggested that high home birth 
rate played role in the low rate of HepB-BD coverage in rural areas in Vietnam (Hipgrave et al., 
2003). In some other countries such as Cambodia, Indonesia and China, home births have been 
reported as important reasons for low coverage of timely HepB-BD (Allison et al., 2017; S. 
Wang et al., 2016).  
Current Vietnam MOH and EPI policies strictly require keeping HepB vaccine in the 
cold chain (2 to 8
o
C) during storage and transportation and until administration (Vietnam 
Ministry of Health, 2012). The lack of refrigerators to keep HepB vaccine at cold temperature (2 
to 8
o
C) contributes to the unavailability of vaccine at commune health centers in remote areas, 
thus to the unavailability of vaccine for home birth. HepB vaccine is heat stable, making it 
suitable for storage outside of cold temperature at 37
o
C for 1 month and at 45
o
C for 1 week, 
without a change in vaccine quality; therefore the WHO supports out-of-cold-chain (OCC) 
strategy for improving HepB-BD coverage in hard to reach areas (World Health Organization, 
2006, 2017b). Lao People’s Democratic Republic (Lao-PDR), a neighboring country of Vietnam, 
recently conducted a pilot study in which Hepatitis B vaccine was stored outside of cold 
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temperature for up to 28 days before being used for birth dose immunization. The study proved 
that the vaccine was still effective and safe for immunizing infants after 28 days outside of cold 
chain. OCC strategy demonstrated its effectiveness, with an increase of 27% in immunizing 
Hepatitis B vaccine for infants within the first 24 hours after birth compared to baseline, with no 
reported complications due to vaccination (Kolwaite et al., 2016). A study in China, which 
utilized a village-based, OCC delivery strategy, showed that the use of vaccine stored outside of 
cold temperature significantly increased the rate of timely HepB-BD. The study results showed 
rates increased from 60% to almost 90% in facility birth group and 25% to almost 66% in home 
birth groups (L. Wang et al., 2007). Wang and colleagues discussed that OCC strategy was more 
effective in increasing the coverage of vaccination in the remote area where the facility birth rate 
was respectively low. According to this group, in this strategy, the help of local health workers 
and commune leaders were the most facilitators for the implementation (S. Wang et al., 2016).    
AEFIs could be a reason for the dramatic decline in the coverage for both HepB3 and 
HepB-BD, according to Technical Advisory Group on Immunization and Vaccine-Preventable 
Diseases in the Western Pacific Region (An et al., 2016). It has been widely reported that the 
HepB immunization coverage in Vietnam, including HepB-BD, was strongly affected by media 
reports on illness or deaths after HepB vaccination. In 2007 and 2013, the rate of HepB 
vaccination including HepB-BD dropped dramatically compared to the previous year, partially 
due to media reports of AEFIs with either monovalent or pentavalent vaccine (Li et al., 2016; 
Tran et al., 2018). Despites the investigation and confirmation by the WHO that the reasons for 
the fatal AEFIs and many of the non-fatal AEFIs in Vietnam were not related to vaccine safety 
and were purely coincidental, the widespread media reports on these events led to major 
reduction in HepB vaccination in the country (Figure 2). Report from an EPI cluster survey in 
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several provinces indicated that in 2009, heath staff continued to refer to the negative impact of 
AEFIs in 2007 (T. D. Nguyen et al., 2015). As confirmed by the Global Advisory Committee on 
Vaccine Safety (GACVS), HepB vaccine has an excellent safety profile, with minimal adverse 
reactions which occur mostly within 24 hours (World Health Organization, 2017b). As the MOH 
decided to temporarily suspend the administration of HepB vaccine after AEFIs for further 
investigation, the public misunderstood that there was a problem with the quality of the vaccine. 
AEFIs in 2007 also affected health providers’ attitude; concern about vaccine quality made 
health staff’s hesitant to prescribe vaccination for newborns (H. T. Duong et al., 2011). It is 
critical important that the MOH provides re-training to healthcare staff at birth facilities and 
vaccination facilities after AEFIs to reassure healthcare providers about the vaccine safety and 
increase their perceived benefits of HepB-BD immunization, as well as improve their practical 
skills on infant immunization and communication with mothers and families to encourage HepB-
BD immunization. Strengthening the AEFI surveillance system to identify causality of AEFIs 
and rapidly inform and reassure healthcare providers and the public, increasing public 
knowledge on the benefit of HepB-BD immunization and vaccination safety by social marketing, 
and increasing community engagement in adoption HepB-BD practice have been discussed to be 
facilitators for high coverage rates in Vietnam (H. T. Duong et al., 2011; T. D. Nguyen et al., 
2015). 
A number of articles have described various types of implementation intervention to 
increase HepB-BD rate in China, and related influential factors on HepB-BD coverage (S. Wang 
et al., 2016). Recipients of care- or community-oriented interventions involve health education 
for pregnant women and their families. Provider-oriented interventions involve health education 
and training for health care provider to improve their awareness and responsibility for 
 Page 20 of 54 
 
administering timely birth dose, mechanisms for payment/incentive/punishment, and improved 
monitoring and supervision. Health system-oriented interventions involve quality improvement 
of the vaccine delivery services, improved access to services via central and local policies, laws, 
regulations and guidelines, integration of immunization services with other services, centralized 
registration, and improved management system for pregnant women. Table 4 presents a 
summary of influential factors to HepB-BD immunization reported for China.   
  
Potential use of Consolidated Framework for Implementation Research 
(CFIR) for identifying facilitators and barriers to vaccine uptake 
Systematic identification and accurate characterization of the facilitators and barriers to 
full implementation of HepB-BD immunization policy in various health care settings could 
inform effective implementation strategies for timely birth dose vaccination. CFIR has been used 
for identifying facilitators and barriers to the uptake of Human Papillomavirus (HPV) vaccine in 
both developed and developing countries (Garbutt et al., 2018a, 2018b; Selove, Foster, Mack, 
Sanderson, & Hull, 2017; Soi et al., 2018). CFIR classifies 36 implementation constructs 
(variables) under 5 major domains that influence successful implementation of evidence-based 
interventions (Table 5). The 5 domains include characteristics of the intervention itself (in this 
case, use of HepB vaccine for timely birth dose immunization), the inner setting (e.g. hospitals, 
clinics or commune health stations that provide HepB vaccination to newborns), the outer setting 
(the context in which the vaccine practice resides), individual characteristics of the implementers 
(e.g. the healthcare providers/workers, nurses, skilled birth attendance), and the process used for 
implementation of the intervention (in this case, administration of HepB vaccine to newborns 
within the first 24 hours of birth). Multiple components (constructs) of the 5 domains interact in 
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rich and complex ways at multiple interacting levels (recipients of care, providers, organizations, 
and social, political and cultural contexts) with wide variation in settings and local contexts to 
influence immunization rate, effectiveness and sustainability. 
Applying in Vietnam, CFIR can guide the interview of public health leaders, 
professionals and health care workers who have been directly involved in the planning, 
implementation, and evaluation of the HepB-BD immunization program. To have a 
comprehensive understanding of variables contributing to the success of the HepB-BD 
implementation, key informants would be those on leadership positions at Vietnam MOH, 
provincial DOH and hospitals at national and provincial levels, who are decision makers, 
supervisors or monitors of the program. Key informants would also be technical staff, medical 
doctors, nurses and birth attendance at local facilities of various settings and geographic areas, 
who work directly with pregnant women and infants. Key informants would also be 
immunization program donors and implementing partners, who are involved in the EPI. Mix 
method studies can be designed to include leadership and healthcare provider interviews using 
the CFIR to guide the data collection and analysis, and the analysis of HepB-BD vaccination rate 
with data abstracted from routine EPI quarterly reports. The information obtained from the 
analysis can be useful to develop effective implementation strategies and/or local and context 
appropriate policies with the aim of increasing HepB-BD coverage rate. Interrupted time-series 
designs can be utilized to evaluate the effectiveness of implementation strategy or new policy 
roll-outs to the practice outcome of interest and the rate of HepB-BD coverage measured at 
multiple time points prior to and after the implementation effort. 
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IMPLICATIONS FOR THE DEVELOPMENT OF IMPLEMENTATION 
STRATEGIES AND POLICIES TO INCREASE THE RATE OF HEPB-BD 
COVERAGE IN VIETNAM 
Using mathematical modeling, Li and coworkers estimated that if HepB-BD and HepB3 
coverage could both reach the target of 95% while the size of birth cohorts remained constant, 
every year, around 51,000 deaths could be prevented and 265,000 chronic infections could be 
avoided through HepB national immunization program (Li et al., 2016). The Vietnamese 
national action plan 2018-2030 aims at decreasing the prevalence of HBsAg positive children 
less than 5 years of age to ≤0.1% by 2030, and the percentage of infants getting within 24-hour 
HepB-BD at least 80% by 2020, 85% by 2025, and 90% by 2030. The MOH would consider 
developing effective tools to identify systematic facilitators and barriers to the rate of HepB-BD 
coverage, followed by development of appropriate policies and implementation strategies to 
address strong positive or negative facilitators and barriers to HepB-BD practice. CFIR can be a 
useful tool to guide the development of such policies and implementation strategies. Although 
the framework has not been applied to the vaccination practice in Vietnam, CFIR has been used 
in healthcare sector as a guide to assess factors that influence implementation of tobacco use 
treatment guidelines in the country (Shelley, VanDevanter, Cleland, Nguyen, & Nguyen, 2015; 
VanDevanter et al., 2017). 
In Vietnam, the rate of deliveries attended by trained health personnel in 2015 was more 
than 98% countrywide and 92% in rural and mountainous areas (Vietnam Ministry of Health, 
2017), so administering timely HepB-BD at birth facilities plays an important role in increasing 
the rate of HepB-BD coverage. Subsidizing strategy can be considered given to mothers in rural 
and underserved areas to encourage them giving birth in facilities. The readily availability of 
 Page 23 of 54 
 
HepB vaccine in all birth facilities and commune health centers will also facilitate the timely 
HepB-BD immunization for newborns.  
In areas with low birth rate or high home birth rate, OCC strategy and community 
engagement strategy can be effective in increasing HepB-BD coverage rate. In addition to 
facilitating timely HepB-BD immunization, OCC strategy would resolve the cost of HepB-BD 
immunization, and also reduce commune health care workload (Murakami et al., 2008). 
 
REFLECTION ON LEADERSHIP ROLE 
If I was in a leadership position in Vietnam MOH, I would call for the establishment of 
Advisory Group(s) and Technical Working Group(s) to develop a 10-year strategic plan, which 
involves the following activities: 
Year 1 (2020): 
1. Identify key national and international stakeholders to include in the process of 
strategic plan development, implementation and evaluation.    
2. Conduct a national-level implementation research study or multiple sub-
national level implementation research studies, which use the CFIR as a tool for 
assessing strong facilitators and barriers at multiple levels to the increased rate 
of HepB-BD coverage. 
3. Based on research findings, decide and develop local and context-appropriated 
implementation intervention(s) to promote facilitators and/or to overcome 
barriers that are most likely associated with and strongly affect the rate of 
HepB-BD coverage. 
 Page 24 of 54 
 
4. Establish a shared vision for assuring every child receives HepB-BD coverage 
in a timely and effective manner. Develop appropriate policy or policies to 
facilitate the chosen implementation intervention(s).  
5. Provide training to healthcare providers (leaders, technical staff, nurses etc.) to 
increase the adoption of new policy and implementation strategy; encourage 
healthcare settings to implement intervention(s) as a quality improvement 
project.  
6. Establish a Technical Working Group on HepB-BD which includes a manager 
and a technical officer from the Department of Preventive Medicine - MOH, a 
manager and technical officer from NIHE (the leading institute in the country in 
preventive medicine), a manager and a technical officer from the 63 provincial 
DOHs. This group will meet every 6 month to review the situation of 
implementation intervention, exchange implementation experiences, and 
address specific emerging issues during implementation. This group will also 
serve as a consulting group for the MOH in regards to the HepB-BD 
implementation.  
From Year 2 to Year 5 (2021-2024): 
7. Conduct quarterly monitoring and supervision to randomly selected sites ensure 
the intervention(s) are properly implemented and correctly reported.   
8. Review nationwide reports every 6 months to identify systematic problems 
and/or site-specific problems. 
9. If there is a systematic problem, call for Advisory Group meetings to suggest 
solution to the problem. 
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10. If there is a site-specific problem, conduct ad-hoc supervision to observe and 
resolve problem as it occurs. 
From Year 6 to Year 9 (2025-2028): 
11. In the first quarter of year 6, Technical Working Group(s) and Advisory 
Group(s) review 4-year (2021-2024) implementation data and reports, along 
with routine reports from the EPI, to evaluate the effectiveness of the 
implementation interventions to the increase of HepB-BD coverage.  
12. Revise the implementation plan and develop new implementation 
intervention(s) as needed.  
13. Follow steps as described for year 2 to 5 (item 5, 6, 7 and 8). 
Year 10 (2029): 
14. Technical Working Group(s) and Advisory Group(s) review 4-year (2025-
2028) implementation data and reports, along with routine reports from the EPI, 
to evaluate the effectiveness of the implementation interventions to the increase 
of HepB-BD coverage.   
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APPENDIX: FIGURES AND TABLES 
  
 
 
Figure 1. Diagram of Hepatitis B Virus structure  
(retrieved from the internet).  
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Figure 2. Rate of 3-dose HepB (HepB3) and HepB-BD coverage in Vietnam from 2003 to 2017  
Source: (World Health Organization, 2019) 
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Figure 3. Rates of HepB-BD coverage in 63 cities and provinces in Vietnam from 2012 to 2015 
Data from the first 3 quarters of each year (Source: Vietnam EPI; http://tiemchungmorong.vn/vi/content/thong-ke-tcmr.html)    
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Table 1. Typical schedule for administration of HepB monovalent and pentavalent vaccines in Vietnam since 2010 
(Vietnam MOH, 2010) 
Age Vaccine 
At birth (within 24 hours) HepB monovalent 
2 months Pentavalent DTP-HepB-Hib* dose 1 
3 months Pentavalent DTP-HepB-Hib dose 2 
4 months Pentavalent DTP-HepB-Hib dose 3 
 
*DTP-HepB-Hib: Diphtheria, Pertussis, Tetanus (DTP), HepB, Haemophilus influenzae B (Hib) 
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Table 2. Research questions, inclusion criteria and data to be extracted if available  
Question Inclusion criteria Data extracted 
What is the effectiveness of 
vaccination policy and program on 
HepB-BD coverage? 
Studies conducted in Vietnam since 2003 * Rates of Hep-BD coverage, assessment of HepB prevalence 
and chronic HepB infection in children less than 10 years of 
age  
What is the cost associated with 
HepB-BD implementation? 
Any review paper or assessment studies 
conducted in Vietnam since 2003 
Data on HepB-BD implementation cost and cost-
effectiveness  
What are influential factors on the rate 
of HepB-BD coverage? 
Any review paper or studies using 
qualitative or mixed methods conducted in 
Vietnam since 2006** 
Knowledge, attitudes and skills among pregnant women, 
health care workers and other stakeholders; health service 
and system factors; social demographic and political 
constrains.  
What interventions or strategies have 
been used to increase the rate HepB-
BD coverage?  
Any study design (except clinical trial) or  
review paper on intervention or strategy 
design, implementation and/or evaluation 
since 2006 
Characteristics of interventions or strategies to improve 
HepB-BD coverage 
* HepB-BD immunization program was nationwide implemented in Vietnam in 2006 
** HepB-BD was introduced to the EPI in 2003   
 Page 31 of 54 
 
Table 3. Rate of HepB-BD coverage in Vietnam, and cost and influential factors associated with implementation of HepB-BD 
immunization  
Reference Study design Province/ 
Region 
Year of 
study 
Participants Sample size Research 
outcome 
reported 
Reported finding on HepB-BD 
immunization 
In  English 
(T. H. 
Nguyen et 
al., 2014) 
Cross-
sectional 
survey 
  
 2000 to 
2008 
Children <15 
y/o 
6,949 HBV 
prevalence as 
an outcome of 
the national 
immunization 
program 
HBsAg prevalence in children with 3+ 
doses of Hep B vaccine including a BD 
was significantly lower than among 
those with 3+ doses but lacked a BD.  
Infants receiving HepB vaccine >7 
days after birth had significantly higher 
HBsAg prevalence than those 
vaccinated 0-1 day after birth 
HBsAg prevalence was significantly 
higher in children of ethnic groups 
compared to those with Kinh ethnicity.  
 HBsAg prevalence was significantly 
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higher in children born at home versus 
at health facility. 
(Li et al., 
2016) 
Mathematical 
model  
Nationwide  2013 Surviving 
infants in 
2013 
1,782,720 Burden of 
HepB disease 
as an outcome 
of the failure in 
HepB 
immunization 
program 
An estimation of >90,000 excessive 
HBV chronic infections and >17,000 
deaths would occur in children born in 
2013 due to the drop in HepB 
immunization coverage in 2013 
compared to 2012.   
(Murakami et 
al., 2008) 
Qualitative 
study (key 
informant 
interview, 
focus group 
discussions, 
surveys) 
Ninh Binh, 
Nghe An, Ho 
Chi Minh 
city, Ca Mau 
2004 Community 
health 
workers, 
mothers of 
infants  
- Cost associated 
with providing 
HepB-BD; 
influential 
factors 
Total incremental cost per birth < 0.7 
USD  
Reported influential factors included: 
vaccine storage sites, pregnancy 
tracking in communities, practice of 
large urban public hospitals and private 
maternity services, interpretation of 
HepB-BD contraindications, and 
family perceptions. 
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(T. D. 
Nguyen et 
al., 2015) 
Cluster 
surveys 
 
Review of 
EPI routine 
data  
Northern 
mountain, 
Red River 
Delta, 
Central, 
Central 
Highland, 
South East, 
South West  
2003 
and 
2009 
 
2001 to 
2008 
Children 0-
23 months 
6,840 
 
7,200 
 
 
HepB3 
coverage;  
HepB-BD 
coverage; 
influential 
factors 
Low HepB-BD coverage rate in all 
surveyed provinces 
Reported influential factors included: 
delayed vaccination services in the 
mountainous and remote provinces  
(Pham et al., 
2018) 
Cross-
sectional 
survey 
Can Tho, 
Vinh Long, 
Ca Mau 
2015 - 
2016 
Infants 6-11 
months 
492 HepB-BD 
coverage; 
influential 
factors 
Reported influential factors included: 
place of birth; distance to vaccination 
place; transportation means; education 
of parents; attitude of health care 
workers; and health conditions of 
infants.  
In Vietnamese 
(A. D. Duong 
et al., 2017) 
Cross-
sectional 
Lang Son 2015-
2016 
Health care 
workers 
114 
 
HepB3 
coverage; 
Rate of timely HepB-BD coverage was 
the lowest among all required 
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survey 
Review of 
children 
vaccination 
records 
provided by 
the clinics and 
families 
Mothers of 
children 12-
23 months 
old 
Children 12-
23 months 
old 
 
323 
 
 
 
 
544 
HepB-BD 
coverage; 
influential 
factors 
immunization under the EPI.  
Reported influential factors included: 
knowledge, attitude and behaviors of 
mothers; and knowledge of health care 
workers.    
(T. H. Duong 
et al., 2016) 
Cross-
sectional 
survey 
Review of 
children 
vaccination 
records 
provided by 
the clinics and 
families 
Bac Giang 2015 Mothers of 
0-3 month 
old 
newborns  
Newborns 
aged 0-3 
months 
330 
 
 
 
330 
HepB-BD 
coverage; 
influential 
factors 
Rate of timely HepB-BD coverage in 
surveyed newborns were 55.2% 
Reported influential factors included: 
type of birth facilities; vaccination 
process in the birth facilities; 
availability of vaccine at the facilities; 
availability of vaccination services on 
weekends and holidays; knowledge, 
attitude and behavior of health care 
providers and parents; mothers’ 
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education level; duration that mothers 
stay in the facilities after giving birth 
(more or less than 24 hours); and 
health conditions of the newborns.  
(H. T. 
Duong, 
Nguyen, Le, 
& Ly, 2011) 
Implementatio
n intervention 
 
In-person 
interview 
 
Review 
vaccination 
records  
Hai Duong  2010-
2011 
Health 
managers 
and health 
care workers  
 
 
Infants 0-4 
months 
- 
 
 
 
 
 
8990  
Influential 
factors on 
implementatio
n interventions 
to increase the 
rate of HepB-
BD coverage 
HepB-BD coverage rate increased 
from 16% to >92% after 1 year of 
intervention implementation  
Influential factors include: training to 
health managers and health care 
workers to increase knowledge and 
practice on HepB-BD immunization, 
cold chain infrastructure for storing 
HepB vaccine at medical facilities, 
public knowledge on HepB-BD and 
vaccination safety, and community 
engagement. 
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Table 4. Factors influencing timely HepB-BD immunization in China  
(Wang, Smith, Peng, Xu, & Wang, 2016) 
Level Influential factors Facilitators Barriers 
Health system Supply and procurement  Lack of vaccines and vaccination services 
in rural and remote areas 
 
Weak surveillance and reporting system on 
pregnant women management  
Lack of or non compliance to regulation 
and guidelines 
Inadequate supervision 
 Knowledge, skills, and 
perception/motivation of health 
care providers 
  
 System rewards and 
punishment 
 Lack of well-design systems for rewarding 
or punishing for performance 
 Management and cooperation  Lack of written protocol for 
communication and coordination between 
maternity and childcare settings and other 
governmental departments 
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Recipients of care Awareness and knowledge  Lack of awareness and knowledge of 
parents and families including cultural 
factors 
 Accessibility to a health facility 
for delivery 
  
Social and political 
context  
Political commitment  The will of influential people and the 
support of the central local government  
Political will and national commitment  
 
 Social context Policies, laws, regulations and guidelines to 
promote hospital birth, require obstetrical 
nurse who deliver babies to administer the 
HepB-BD within 24 hours after birth 
Infant HepB vaccination was added to the 
national immunization program 
 
 International cooperation  Funding support from the government and 
international donors 
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Table 5. Summary of Consolidated Framework for Implementation Research (CFIR) constructs  
(National Collaborating Center for Methods and Tools, 2014) 
Domain Number of constructs  Related factors  
Intervention Characteristics 8 Characteristics of the intervention being implemented into a particular organization 
Outer Setting 4 Economic, political and social context factors within which an organization resides 
Inner Setting 12 Structural, political and cultural context features through which the implementation 
process will proceed 
Characteristics of Individuals 5 Individuals involved with the intervention and/or implementation process 
Process  7 Essential activities of the implementation process that are common across 
organizational change models  
 
More information about the CFIR constructs and tools can be found at https://cfirguide.org/ 
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